Obinutuzumab administration
Phase 3Small molecule
Obinutuzumab administration is one of 51 small molecule programs targeting Lupus Nephritis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Lupus Nephritis
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Medrol
PfizerApproved
Rituxan
RocheApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Farxiga
AstraZenecaApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Myfortic
NovartisApproved
Imuran
LLegacy Health System
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lupkynis
Aurinia PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Obinutuzumab administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details